Has Roberto Unda Gomez, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,080 in general payments to Roberto Unda Gomez, MD across 32 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Roberto Unda Gomez, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Roberto Unda Gomez, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Roberto Unda Gomez, MD

General Practice · San Juan, PRNPI 1558462754

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 32 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 9 manufacturers, the largest accounting for just 21.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $664 and has fallen 96.2% since, to $25 in 2024.

$1,080in general payments, 2019–2025

Across 32 payments — averaging $33.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Sanofi-aventis U.S. LLC$229
Pfizer Pharmaceuticals LLC$218
Lilly USA, LLC$200
PBG Puerto Rico LLC$146
E.r. Squibb & Sons, L.L.C.$100
Johnson & Johnson$89
plus $97 from 3 others

$85,098in research payments, 2019–2025

Across 9 payments — averaging $9455.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Eli Lilly$59K
Sanofi US Services Inc.$26K

What the payments were for

Food & beverage$1,080100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Sanofi-aventis U.S. LLC	4	$229
Pfizer Pharmaceuticals LLC	2	$218
Lilly USA, LLC	6	$200
PBG Puerto Rico LLC	7	$146
E.r. Squibb & Sons, L.L.C.	4	$100
Johnson & Johnson	3	$89
Mylan LLC	4	$64
Eli Lilly Export S.A. Puerto Rico Branch	1	$22
AstraZeneca	1	$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

ELIQUIS$121
TOUJEO$100

How this compares

$1,080 in reported general payments places this provider in the 85th percentile of 3,586 general practice providers in Puerto Rico.

See all general practice providers in Puerto Rico →

Medicare billing

Part B allowed, 2024

$43,043

Medicare patients

Services billed

283

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Janumet XrSitagliptin Phos/Metformin Hcl	13	$9,772
SynthroidLevothyroxine Sodium	77	$8,908
Memantine Hcl	40	$1,403
Gabapentin	59	$1,338
Rosuvastatin Calcium	71	$1,233
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip	22	$705
Levothyroxine Sodium	43	$627
Duloxetine Hcl	11	$623
SsdSilver Sulfadiazine	11	$585
Donepezil Hcl	18	$488
Meclizine Hcl	13	$486
Losartan Potassium	35	$467
Doxazosin Mesylate	13	$410
Metoprolol Succinate	19	$381
Tamsulosin Hcl	15	$376

Paid to pharmacies, not to this prescriber.

Other general practice in San Juan

William E TorresSan Juan$86K
Vivian Tamayo AgraitSan Juan$64K
Gregorio Cortes-MaisonetSan Juan$26K
Victor PalmerSan Juan$21K
Jose Davila SanchezSan Juan$16K
Hector Cintron ColonSan Juan$10K
Gabriela TorresSan Juan$8K
Orvil MartinezSan Juan$7K
Carlos Henriquez FelipeSan Juan$6K
Rene Echevarria CofinoSan Juan$6K

See the full list for Puerto Rico →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →